Intra-Cellular Therapies (ITCI) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Intra-Cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 9, 2021 7:30 AM ESTCAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021.
Bipolar depression launch preparations are progressing well; sales force expansion is substantially complete.
Total revenues were $22.2 million for the third quarter of 2021, compared to $7.4 million for the same period in the prior year, representing an increase of approximately 200%.
CAPLYTA achieved net product revenues of $21.6 million for the third quarter of 2021. Third quarter CAPLYTA total prescriptions (TRx) increased 15% versus the previous quarter.
Patient enrollment... More
